Adial Pharmaceuticals Inc (ADIL) @ NASDAQ
Printed Monday, 6 July '26 06:14 MST
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.
Biotechnology Pharmaceuticals, Biotechnology & Life Sciences Common Stock β +1.459
| Date | Name (*Public) | Description | Symbol | Type | Size | Action |
|---|
| Date | Value | Error | Logarithmic | Error | Model (*Public) |
|---|
+$0.09 (3.2%) on Thursday, 2 July 2026, Marketcap $6.35 M
| Date | Value | Δ | Open | Close | Low | High | Adjusted | Volume | Δ |
|---|
| Name | Version (*Public) | Indicator % | Auto | Description | Symbol | Company Name | Forecasts | Buy / Sell | Action |
|---|
| Opened (Closed) | Expires | Symbol | Company Name | Name (*Public) | Size | Contract Symbol | Open P/L | Close P/L | Total P/L | ROI | DTE | DIT | Delta | Action |
|---|
| Details | Best Trend by Hindsight | Forecast | Profit or Loss | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date (*Public) | Symbol | Strategy | Data | Origin | Slope | Sigma | Cor % | Moves | Sigma | Moves | Gain % | Periods | Action |
| Date | Name (*Public) | Description | Price | Quantity | Total | Cost | Type | Symbol | Action |
|---|
| Date | RSI | Stochastic %D | Stochastic %K | MACD | MACD Divergence | MACD Signal | DMI | CCI | Volatility | Bollinger Upper | Bollinger Mid | Bollinger Lower |
|---|
| Date | Name | Description | Type | Symbol | Company Name | Location |
|---|
| Date UTC | Location | Action | Description | Object | Severity | User | Action |
|---|
